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Stigma associated with radiation induced bowel 
injury (RBI) has restricted interest in its pathogenesis 
and the pathophysiological processes that occur as a 
consequence. This neglect has in turn hampered clinical 
management and led to the widely held belief that RBIs 
are not amenable to treatment. RBI is more common 
than Crohn’s disease, yet attracts a fraction of the 
research funding. Furthermore, only a ﬁ fth of patients 
with RBI in the UK see a gastroenterologist, and most 
who do so are managed ineﬀ ectively.1
In The Lancet, Jervoise Andreyev and colleagues1 
report ﬁ ndings from one of the ﬁ rst randomised trials 
to show that the symptoms of RBI can be improved by a 
therapeutic intervention. In what will probably be viewed 
as a landmark trial, Andreyev and colleagues random-
ised 218 patients to three groups: algorithm-based treat-
ment led by a gastroenterologist or nurse, or usual care. 
The ﬁ ndings show that in terms of the trial’s primary 
endpoint, the mean diﬀ erence in change in score on the 
IBDQ-B instrument between baseline and 6 months, 
both gastroenterologist-led care (5·47, 95% CI 1·14–9·81; 
p=0·01) and nurse-led care (4·12, 0·04–8·19; p=0·04) 
were superior to usual care; in other words, both men 
and women with a range of RBIs can have clinical and 
statistically signiﬁ cant improvements in their symptoms 
with tailored management programmes determined by 
an investigative and therapeutic algorithm. 
A reasonable question to ask is why a diagnostic 
and therapeutic algorithm should work in a group of 
disorders considered refractory to treatment, without 
the use of new pharmaceutical agents. The answer is 
surprisingly simple. The investigators recognised that RBI 
frequently aﬀ ects several parts of the bowel and almost 
always aﬀ ects several normal physiological processes 
adversely. The identiﬁ cation of these processes (using 
the diagnostic part of the algorithm) therefore enables 
adaptive measures, such as dietary modiﬁ cations and the 
use of commonly prescribed drugs to reduce the severity 
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high-quality evidence that it is of value and should be part 
of the response to triggering of treatment.
With their study, Harris and colleagues have further 
contributed to our understanding of the prevalence and 
timing of low concentrations of blood sugar. In their 
previous analysis of risk groups acquired prospectively on 
the basis of birthweight, gestation, and maternal diabetes, 
the investigators showed that 51% had at least one low 
measurement, 19% had values of less than 2·0 mm ol/L, 
and 19% had recurrent episodes.7 Furthermore, more than 
a third of episodes took place after three normal values 
and 6% of episodes after more than 24 h of birth.
Despite the welcome results of Harris and coworkers’ 
present trial,4 we need further trials to reﬁ ne our 
operational deﬁ nitions. The popular deﬁ nition of 
2·6 mmol/L seems to be based on an extremely small 
num ber of newborn babies in a study of evoked cortical 
potentials and a retrospective assessment of long-term 
low values in a low birthweight feeding study, which is 
hardly robust evidence, and an exhortation to maintain 
generous normoglycaemia in newborn babies.8 Such 
trials can and should be randomised and include out-
come evaluations to strengthen our understanding of 
the association between low blood glucose readings, 
their timecourse, and neurological outcomes; indeed one 
strategy for doing this has been proposed.1 Until more 
information is available, practice will continue to be 
based on uncertain facts; however, use of buccal dextrose 
gel should help to minimise unnecessary interventions.
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of patients’ dysfunctional symptoms. The algorithm 
is provided in the online appendix of the paper, and its 
development is described elsewhere.2
The investigators showed the algorithm-based inter-
vention to be beneﬁ cial for at least 12 months, which 
is encouraging, but how long these beneﬁ ts will last is 
unclear and will need further assessment. It is important 
to note, however, that the intervention cannot be 
expected to heal the bowel injuries that have led to the 
clinical manifestations.
Future trials should focus on the prophylactic use of 
pharmaceutical agents, perhaps during and after radio-
therapy, given with the intention of limiting severity of 
injuries. Systematic, evidence-based reviews of inter-
ventions to ameliorate gastrointestinal mucositis are 
available.3,4 Moreover, a strategy for how to test new 
poten tial pharmacological agents to protect against 
or mitigate bowel injuries (deﬁ ned as agents that are 
given after irradiation, but before the development of 
symptoms) has been suggested.5 Much work has been 
done in the past 5–10 years to develop medical counter-
measures against radiation. Many of these eﬀ orts are 
directed towards reducing gastrointestinal radia tion 
toxi city, and several agents are undergoing ad vanced 
develop ment and are en route to US Food and Drug 
Administration (FDA) approval. Although the pri-
mary intent is to enhance preparedness in the event of 
a radiological or nuclear emergency, many agents that 
reduce short-term or long-term side-eﬀ ects of radiation 
in the emergency setting can probably also beneﬁ t cancer 
survivors, and vice versa.
Andreyev and colleagues’ ﬁ ndings1 have shown that 
their algorithm can be used just as eﬀ ectively by speciﬁ c-
ally trained nurses as by gastroenterologists. The trial 
results will hopefully promote an improved under-
standing of pathophysiologies of RBI and the adoption 
of the algorithm into the training programmes of 
specialist oncology nurses. Such a development would 
do much to further the translation of the results into 
clinical practice. Of course, this possibility does not mean 
that gastroenterologists need no longer bother about 
radi ation injury. Nothing would be better for patients 
with RBI than if the gastroenterological community 
was to take ownership of this group of disorders and 
make sure that the breakthrough achieved by Andreyev 
and colleagues is just the ﬁ rst of many. The provision 
of part-time appoint ments of gastroenterologists at 
large cancer treat ment centres would also do much to 
reduce the burden of RBI across the world and stimulate 
treatment advances.
A pertinent question is whether the major technical 
advances in radiotherapy delivery in the past 15 years 
will lead to reductions in RBI. The answer is both yes 
and no. Although new technology will allow many 
radiation oncologists to reduce radiation doses to the 
bowel, many more will be beguiled into irradiating 
what they perceive to be new intra-abdominal targets 
(such as lymph-node drainage regions and organs not 
commonly treated) or into escalating radiation doses 
to existing targets. Available data show that limiting 
dose to the rectum during prostatic radiation without 
increasing dose to the prostate itself will cause dramatic 
reductions to symptoms related to rectal injury.6 Some 
data also indicate that increased dosing to the prostate 
can be achieved without increased rectal injury,7 but this 
ﬁ nding has not been shown elsewhere.8
The results of Andreyev and coworkers’ trial should 
be widely heeded and the algorithm taken into routine 
clinical practice. This is no more than patients who survive 
cancer treatment but go on to develop RBI deserve.
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